vs
Side-by-side financial comparison of NovoCure Ltd (NVCR) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
NovoCure Ltd is the larger business by last-quarter revenue ($174.1M vs $151.1M, roughly 1.2× STURM RUGER & CO INC). On growth, NovoCure Ltd posted the faster year-over-year revenue change (12.3% vs 3.6%). Over the past eight quarters, NovoCure Ltd's revenue compounded faster (7.6% CAGR vs 5.1%).
NovoCure Ltd is a global oncology company that develops and commercializes innovative Tumor Treating Fields (TTFields) therapy, a non-invasive wearable treatment using low-intensity electric fields to disrupt cancer cell division. Its approved therapies target glioblastoma, malignant mesothelioma and non-small cell lung cancer, serving patients across North America, Europe and Asia Pacific.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
NVCR vs RGR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $174.1M | $151.1M |
| Net Profit | $-71.1M | — |
| Gross Margin | 77.6% | 17.8% |
| Operating Margin | — | 2.3% |
| Net Margin | -40.9% | — |
| Revenue YoY | 12.3% | 3.6% |
| Net Profit YoY | -107.3% | — |
| EPS (diluted) | — | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $174.1M | — | ||
| Q4 25 | $174.3M | $151.1M | ||
| Q3 25 | $167.2M | $126.8M | ||
| Q2 25 | $158.8M | $132.5M | ||
| Q1 25 | $155.0M | $135.7M | ||
| Q4 24 | $161.3M | $145.8M | ||
| Q3 24 | $155.1M | $122.3M | ||
| Q2 24 | $150.4M | $130.8M |
| Q1 26 | $-71.1M | — | ||
| Q4 25 | $-24.5M | — | ||
| Q3 25 | $-37.3M | $1.6M | ||
| Q2 25 | $-40.1M | $-17.2M | ||
| Q1 25 | $-34.3M | $7.8M | ||
| Q4 24 | $-65.9M | — | ||
| Q3 24 | $-30.6M | $4.7M | ||
| Q2 24 | $-33.4M | $8.3M |
| Q1 26 | 77.6% | — | ||
| Q4 25 | 75.8% | 17.8% | ||
| Q3 25 | 73.2% | 15.1% | ||
| Q2 25 | 73.9% | 3.9% | ||
| Q1 25 | 75.1% | 22.0% | ||
| Q4 24 | 79.2% | 22.8% | ||
| Q3 24 | 77.2% | 18.5% | ||
| Q2 24 | 77.0% | 22.3% |
| Q1 26 | — | — | ||
| Q4 25 | -23.2% | 2.3% | ||
| Q3 25 | -21.5% | -2.7% | ||
| Q2 25 | -24.9% | -15.6% | ||
| Q1 25 | -24.4% | 6.2% | ||
| Q4 24 | -39.3% | 7.8% | ||
| Q3 24 | -20.7% | 3.1% | ||
| Q2 24 | -22.3% | 6.9% |
| Q1 26 | -40.9% | — | ||
| Q4 25 | -14.1% | — | ||
| Q3 25 | -22.3% | 1.2% | ||
| Q2 25 | -25.3% | -13.0% | ||
| Q1 25 | -22.1% | 5.7% | ||
| Q4 24 | -40.9% | — | ||
| Q3 24 | -19.7% | 3.9% | ||
| Q2 24 | -22.2% | 6.3% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.22 | $0.22 | ||
| Q3 25 | $-0.33 | $0.10 | ||
| Q2 25 | $-0.36 | $-1.05 | ||
| Q1 25 | $-0.31 | $0.46 | ||
| Q4 24 | $-0.61 | $0.62 | ||
| Q3 24 | $-0.28 | $0.28 | ||
| Q2 24 | $-0.31 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $432.0M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $330.7M | $283.8M |
| Total Assets | $787.9M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $432.0M | — | ||
| Q4 25 | $93.5M | $92.5M | ||
| Q3 25 | $342.1M | $80.8M | ||
| Q2 25 | $149.6M | $101.4M | ||
| Q1 25 | $127.3M | $108.3M | ||
| Q4 24 | $163.8M | $105.5M | ||
| Q3 24 | $185.4M | $96.0M | ||
| Q2 24 | $164.8M | $105.6M |
| Q1 26 | $330.7M | — | ||
| Q4 25 | $340.5M | $283.8M | ||
| Q3 25 | $341.3M | $279.6M | ||
| Q2 25 | $349.4M | $289.3M | ||
| Q1 25 | $362.0M | $321.5M | ||
| Q4 24 | $360.2M | $319.6M | ||
| Q3 24 | $360.8M | $314.9M | ||
| Q2 24 | $361.8M | $321.5M |
| Q1 26 | $787.9M | — | ||
| Q4 25 | $804.3M | $342.0M | ||
| Q3 25 | $1.4B | $342.3M | ||
| Q2 25 | $1.2B | $349.5M | ||
| Q1 25 | $1.2B | $379.0M | ||
| Q4 24 | $1.2B | $384.0M | ||
| Q3 24 | $1.2B | $373.5M | ||
| Q2 24 | $1.2B | $376.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.5M |
| Free Cash FlowOCF − Capex | — | $12.3M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | — | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.0M | $15.5M | ||
| Q3 25 | $20.6M | $12.9M | ||
| Q2 25 | $-15.9M | $14.7M | ||
| Q1 25 | $-35.7M | $11.1M | ||
| Q4 24 | $-3.5M | $20.0M | ||
| Q3 24 | $10.4M | $9.4M | ||
| Q2 24 | $-1.7M | $18.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-22.9M | $12.3M | ||
| Q3 25 | $14.9M | $7.0M | ||
| Q2 25 | $-21.4M | $9.1M | ||
| Q1 25 | $-46.3M | $10.0M | ||
| Q4 24 | $-12.4M | $16.4M | ||
| Q3 24 | $-307.0K | $2.6M | ||
| Q2 24 | $-13.2M | $10.1M |
| Q1 26 | — | — | ||
| Q4 25 | -13.1% | 8.2% | ||
| Q3 25 | 8.9% | 5.5% | ||
| Q2 25 | -13.5% | 6.9% | ||
| Q1 25 | -29.9% | 7.4% | ||
| Q4 24 | -7.7% | 11.2% | ||
| Q3 24 | -0.2% | 2.1% | ||
| Q2 24 | -8.8% | 7.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 2.1% | ||
| Q3 25 | 3.4% | 4.6% | ||
| Q2 25 | 3.5% | 4.2% | ||
| Q1 25 | 6.8% | 0.8% | ||
| Q4 24 | 5.5% | 2.5% | ||
| Q3 24 | 6.9% | 5.5% | ||
| Q2 24 | 7.6% | 6.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NVCR
Segment breakdown not available.
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
